Navigating EU pharmaceutical, food, and chemical regulations for peptide sales โ with a focus on Slovenia and Croatia
Operating a peptide sales business in the European Union means navigating a complex and often contradictory regulatory landscape. The same substance can be classified as a medicinal product, a novel food, a chemical substance, or simply a research tool โ depending on who you ask, how you market it, and which member state you are standing in. Understanding this framework is not optional; it is the single factor that determines whether your operation is a legitimate business, a regulatory violation, or a criminal offense.
If presented as therapeutic (2001/83/EC). Penalties up to โฌ500K. The highest-risk classification.
If consumed by humans (EU 2015/2283). Requires EFSA authorization โ commercially prohibitive for small vendors.
Under REACH (EC 1907/2006) โ only triggered above 1 ton/year per substance, irrelevant for typical resellers.
The "research use only" safe harbor. The operative classification for grey-market peptide vendors โ imperfect but essential.
The Medicinal Products Directive is the single most important piece of legislation governing peptide sales in Europe. Article 1 defines a "medicinal product" broadly: any substance presented as having properties for treating or preventing disease, or any substance that may be used to restore, correct, or modify physiological functions by pharmacological, immunological, or metabolic action.
Immediate danger zone. The moment you describe BPC-157 as supporting "gut healing" or "tissue repair," you have presented it as a medicinal product. Even implied claims โ "for joint health," "recovery support" โ trigger this classification.
Based on what the substance actually does pharmacologically. Harder to escape, but enforcement agencies rarely pursue this prong alone for small-volume sellers.
The legal loophole that keeps the entire grey-market peptide industry alive. By explicitly stating that peptides are sold exclusively for in vitro research, laboratory analysis, and chemical testing โ and not for human or veterinary consumption โ vendors attempt to stay outside the medicinal product definition.
โ ๏ธ Caveat: The disclaimer works as a shield in most jurisdictions, but it is not bulletproof. If a regulator decides you know your customers are injecting your products, the disclaimer becomes a thin legal fiction.
| Jurisdiction | Max Fine (Legal Entity) | Personal Liability | Risk Level |
|---|---|---|---|
| ๐ธ๐ฎ Slovenia | โฌ500,000 | Yes โ individuals face personal criminal liability | HIGH |
| ๐ญ๐ท Croatia | ~โฌ300,000 | Yes โ personal liability for responsible individuals | MEDIUM |
| ๐ช๐บ Other EU | Varies (โฌ100Kโโฌ500K) | Varies by member state | MEDIUM |
A novel food is any food not used for human consumption to a significant degree within the EU before 15 May 1997. While peptides are sold as research chemicals โ not food โ some member state agencies have taken the position that if a substance is ingested by humans (even voluntarily), it falls under this regulation.
BPC-157 has been called out under Novel Food in certain jurisdictions. Origin story at University of Zagreb creates some protection in Croatia, but the regulatory risk remains.
EFSA authorization costs โฌ100Kโโฌ500K and takes 12โ36 months. Commercially impossible for small resellers.
Focuses resources on products clearly marketed as medicines or supplements, not small research chemical vendors.
Similar to JAZMP. Cultural factor: BPC-157 was discovered at University of Zagreb, creating a notably less aggressive enforcement environment.
REACH governs the import and manufacture of chemical substances. Registration is required for any company importing over one metric ton per year of a chemical substance.
Typical medium-sized reseller: 10โ50 kg/year across all peptides. Each peptide is a separate substance โ you'd need 1,000+ kg of a single peptide to trigger registration.
At โฌ50โโฌ200/gram, ton-scale = โฌ50M+ revenue. Far outside small-vendor category. REACH is not a concern for typical peptide resellers.
Slovenia is the most common base for European peptide resellers: favorable tax environment, pragmatic JAZMP enforcement, and full EU single market access.
JAZMP prioritizes counterfeit medicines, products with explicit therapeutic claims, and pharmacy-channel sales. A website selling to "research laboratories only" with proper disclaimers is unlikely to attract attention.
If a competitor, dissatisfied customer, or concerned citizen files a complaint, JAZMP is obligated to follow up. Operate cleanly: no therapeutic claims, proper disclaimers, age verification, clear ToS.
The choice of business entity is one of the most consequential decisions you will make. Here is the strategic comparison:
| Factor | s.p. (Sole Proprietor) | d.o.o. (Limited Company) |
|---|---|---|
| Liability | Unlimited โ personal assets at risk | Limited โ separate legal entity |
| Effective Tax Rate | 4โ6% (normirani stroลกki regime) | 22% (corporate + dividend withholding) |
| Setup Cost | ~โฌ0 โ online in under 1 hour | โฌ4,000โโฌ5,000 (notary, registration, legal) |
| Min Capital | None | โฌ7,500 (โฌ5,000 cash + โฌ2,500 in-kind) |
| Accounting | โฌ50โโฌ100/month | โฌ200โโฌ500/month + annual financial statements |
| Tax Base | 20% of revenue (80% deemed expenses) | Actual profit |
| Recommended For | Year 1โ2 startup phase | Year 2โ3+ mature operation |
๐ก Strategic Recommendation: Two-phase approach โ start as an s.p. under the normirani stroลกki regime for Year 1 (minimal tax cost, test the model). If the business proves viable, convert to a d.o.o. in Year 2 or 3 for liability protection. When regulatory attention comes, it is far better to face it through a limited liability company where your personal savings, home, and assets are protected.
| Rule | Details |
|---|---|
| Standard Rate | 22% on domestic sales |
| Small Business Exemption | Exempt if revenue < โฌ50K/year โ no VAT registration, no returns to file |
| OSS Threshold | โฌ10K in EU distance sales โ most peptide businesses exceed this quickly |
| OSS Filing | Quarterly return in Slovenia, covering all EU sales at destination-country rates |
| Import VAT | 22% paid at border on non-EU imports (reclaimable as input VAT if registered) |
| Destination | VAT Rate | Notes |
|---|---|---|
| ๐ฉ๐ช Germany | 19% | Largest EU market |
| ๐ฆ๐น Austria | 20% | High purchasing power |
| ๐ฎ๐น Italy | 22% | Matches SI domestic rate |
| ๐ญ๐บ Hungary | 27% | Highest EU rate |
| ๐ธ๐ฐ Slovakia | 23% | Other common destinations |
| ๐ต๐ฑ Poland | 23% | |
| ๐จ๐ฟ Czechia | 21% |
Croatia is a secondary but increasingly popular base for peptide operations, particularly for businesses with regional ties.
Generally less aggressive than JAZMP โ partly a resource issue (smaller budget, fewer inspectors) and partly cultural (BPC-157's Zagreb origin story).
10% for companies with revenue under โฌ1M โ significantly lower than Slovenia's effective rate.
Higher personal tax burden, higher social security contributions, and generally more paperwork. Less digital government infrastructure.
25% standard rate. Same OSS rules apply for cross-border EU sales.
| Criterion | Slovenia | Croatia |
|---|---|---|
| Corporate Tax | 22% effective | 10% (revenue < โฌ1M) |
| s.p. Effective Tax | 4โ6% (normirani stroลกki) | Higher (no equivalent regime) |
| VAT Rate | 22% | 25% |
| Regulatory Enforcement | Pragmatic, low priority for research peptides | Less aggressive, cultural understanding of BPC-157 |
| Administration | Smooth, digital | More bureaucratic, less digital |
| Best For | Startups, sole proprietors, digital-first operations | Companies > โฌ1M revenue, HR resident founders |
The fundamental problem: you are selling biologically active substances that your customers are almost certainly injecting into their bodies, despite your disclaimers. If a customer suffers an adverse reaction, you face potential legal liability โ even if your product is pure and your disclaimers are prominent.
Standard business liability insurance explicitly excludes chemical and pharmaceutical products. Most small peptide vendors operate without insurance.
Howden Specialty (Lloyds broker) has quoted policies at โฌ3Kโโฌ8K/year for well-structured businesses. Coverage limited to third-party liability for EU sales, with exclusions for intentional misuse and punitive damages.
Legal separation between business and personal assets. Personal bank accounts, home, and investments protected โ provided no commingling, personal guarantees, or fraud.
Every invoice, ToS page, and product listing must include: "For research / laboratory use only," "Not for human or veterinary consumption," age 18+ confirmation, limitation of liability clause, Slovenian law choice.
Verify shipping addresses (no residential forwarding addresses as "labs"), maintain chain-of-custody for every batch, keep clean records of all customer interactions.
Specify Slovenian law and exclusive Slovenian court jurisdiction. Prevents customers from suing in their home jurisdiction under potentially more favorable laws.
Effective June 2026. New guideline for development and manufacture of synthetic peptides. Signals increased regulatory attention. Covers quality by design, impurity profiling, characterization requirements.
HIGH RISK โ Semaglutide, tirzepatide, and related GLP-1 peptides are drawing intense regulatory scrutiny. Novo Nordisk and Eli Lilly aggressively lobbying for crackdowns. Expect heightened enforcement in 2026+.
| Category | Risk Level | Examples | Recommendation |
|---|---|---|---|
| Research peptides (non-GLP-1) | LOW-MED | BPC-157, TB-500, GHK-Cu | Standard disclaimers, clean operations |
| GLP-1 receptor agonists | HIGH | Semaglutide, Tirzepatide, Retatrutide | Heightened caution, expect enforcement |
| Novel peptides (unregulated) | MEDIUM | SS-31, MOTS-c, AOD9604 | Monitor emerging regulatory guidance |
The legal strategy for a European peptide reseller reduces to a few core principles:
Your primary shield. Imperfect but essential. Prominently displayed on every product page, checkout, and invoice.
Favorable tax regime (normirani stroลกki), pragmatic JAZMP enforcement, EU single market access.
Start as s.p. for tax efficiency, convert to d.o.o. for liability protection as business matures.
Avoid VAT compliance costs as long as possible. Use OSS scheme when you surpass the threshold.
ToS, age verification, liability limitations, governing law clause. Every sale must be documented.
Intense regulatory and pharmaceutical company pressure. Significantly higher risk profile than BPC-157 or TB-500.
The line between a legitimate research chemical supplier and an illegal medicine distributor is drawn by the words on your website. Stay on the right side of that line.